Literature DB >> 26452316

Pharmacokinetics of drugs in pregnancy.

Maisa Feghali1, Raman Venkataramanan2, Steve Caritis3.   

Abstract

Pregnancy is a complex state where changes in maternal physiology have evolved to favor the development and growth of the placenta and the fetus. These adaptations may affect preexisting disease or result in pregnancy-specific disorders. Similarly, variations in physiology may alter the pharmacokinetics or pharmacodynamics that determines drug dosing and effect. It follows that detailed pharmacologic information is required to adjust therapeutic treatment strategies during pregnancy. Understanding both pregnancy physiology and the gestation-specific pharmacology of different agents is necessary to achieve effective treatment and limit maternal and fetal risk. Unfortunately, most drug studies have excluded pregnant women based on often-mistaken concerns regarding fetal risk. Furthermore, over two-thirds of women receive prescription drugs while pregnant, with treatment and dosing strategies based on data from healthy male volunteers and non-pregnant women, and with little adjustment for the complex physiology of pregnancy and its unique disease states. This review will describe basic concepts in pharmacokinetics and their clinical relevance and highlight the variations in pregnancy that may impact the pharmacokinetic properties of medications.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26452316      PMCID: PMC4809631          DOI: 10.1053/j.semperi.2015.08.003

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  83 in total

1.  Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: No evidence for complementary expression.

Authors:  P Mylona; J A Hoyland; C P Sibley
Journal:  Placenta       Date:  1999 Jul-Aug       Impact factor: 3.481

2.  P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages.

Authors:  Anita A Mathias; Jane Hitti; Jashvant D Unadkat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-06-16       Impact factor: 3.619

3.  Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.

Authors:  P Villani; M Floridia; M F Pirillo; M Cusato; E Tamburrini; A F Cavaliere; G Guaraldi; C Vanzini; A Molinari; A degli Antoni; M Regazzi
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

4.  Plasma volume in normal first pregnancy.

Authors:  B B Pirani; D M Campbell; I MacGillivray
Journal:  J Obstet Gynaecol Br Commonw       Date:  1973-10

5.  Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.

Authors:  A Philipson; G Stiernstedt; M Ehrnebo
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

6.  Glucocorticoid regulation of placental breast cancer resistance protein (Bcrp1) in the mouse.

Authors:  Sophie Petropoulos; William Gibb; Stephen G Matthews
Journal:  Reprod Sci       Date:  2011-05-20       Impact factor: 3.060

7.  CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.

Authors:  W J Tamminga; J Wemer; B Oosterhuis; J Weiling; B Wilffert; L F de Leij; R A de Zeeuw; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1999-05       Impact factor: 2.953

8.  Pharmacokinetics of digoxin in pregnancy.

Authors:  A M Luxford; G S Kellaway
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 9.  Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation.

Authors:  Shadi A Qasqas; Camille McPherson; William H Frishman; Uri Elkayam
Journal:  Cardiol Rev       Date:  2004 Jul-Aug       Impact factor: 2.644

Review 10.  Primary and secondary carnitine deficiency syndromes.

Authors:  R Pons; D C De Vivo
Journal:  J Child Neurol       Date:  1995-11       Impact factor: 1.987

View more
  58 in total

1.  Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015.

Authors:  Rosarita Ferrara; Valentina Ientile; Vincenzo Arcoraci; Carmen Ferrajolo; Carlo Piccinni; Andrea Fontana; Salvatore Benvenga; Gianluca Trifirò
Journal:  Endocrine       Date:  2017-02-02       Impact factor: 3.633

Review 2.  An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.

Authors:  Lyrialle W Han; Chunying Gao; Qingcheng Mao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-08-03       Impact factor: 4.481

3.  Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics.

Authors:  Pyry A Välitalo; Heidi Kemppainen; Aida Kulo; Anne Smits; Kristel van Calsteren; Klaus T Olkkola; Jan de Hoon; Catherijne A J Knibbe; Karel Allegaert
Journal:  Br J Clin Pharmacol       Date:  2017-05-14       Impact factor: 4.335

4.  Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.

Authors:  Sarah Badaoui; Ashley M Hopkins; A David Rodrigues; John O Miners; Michael J Sorich; Andrew Rowland
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

5.  An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.

Authors:  Steve N Caritis; Jaime R Bastian; Hongfei Zhang; Hari Kalluri; Dennis English; Michael England; Stephanie Bobby; Raman Venkataramanan
Journal:  Am J Obstet Gynecol       Date:  2017-06-29       Impact factor: 8.661

6.  Patterns and Variability of Endocrine-disrupting Chemicals During Pregnancy: Implications for Understanding the Exposome of Normal Pregnancy.

Authors:  Germaine M Buck Louis; Edwina Yeung; Kurunthachalam Kannan; Joseph Maisog; Cuilin Zhang; Katherine L Grantz; Rajeshwari Sundaram
Journal:  Epidemiology       Date:  2019-11       Impact factor: 4.822

7.  Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.

Authors:  Jeremiah D Momper; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Martina L Badell; Edward P Acosta; Murli Purswani; Elizabeth Smith; Nahida Chakhtoura; Kyunghun Park; Sandra Burchett; David E Shapiro; Mark Mirochnick
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

Review 8.  Anatomical and physiological alterations of pregnancy.

Authors:  Jamil M Kazma; John van den Anker; Karel Allegaert; André Dallmann; Homa K Ahmadzia
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-02-06       Impact factor: 2.745

Review 9.  Pharmacokinetic studies in pregnancy.

Authors:  Michael J Avram
Journal:  Semin Perinatol       Date:  2020-01-27       Impact factor: 3.300

10.  Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.

Authors:  Ahizechukwu C Eke; Jiajia Wang; Khadija Amin; David E Shapiro; Alice Stek; Elizabeth Smith; Nahida Chakhtoura; Michael Basar; Kathleen George; Katherine M Knapp; Esaú C João; Kittipong Rungruengthanakit; Edmund Capparelli; Sandra Burchett; Mark Mirochnick; Brookie M Best
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.